Dealbreaker on MSN2d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough MarketA Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...
The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...
While initial study results suggest Beam's technology can correct alpha-1 antitrypsin deficiency's genetic roots, shares fell ...
The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...
BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in ...
Proton Beam Therapy is highly effective for treating tumours in sensitive areas, since by reducing exposure of healthy ...
The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...
A cutting-edge $500 million facility was subsequently built with its website boasting: “The Australian Bragg Centre for ...
Apollo Hospitals had introduced proton therapy at its cancer centre in 2019 and the hospital says that over 2,000 patients ...
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback